Cyclical hematuria-ureteral endometriosis: a case report

Little attention has been paid for the renal involvement in endometriosis, a rare and silent disorder which ultimately lead to renal failure. Involvement most commonly may be limited to single ureter (left one) and it is usually involvement extrinsically. Although cases have been reported in the literature, true incidence of ureteral involvement is still not known. The diagnosis is difficult as the disease has non-specific symptoms. Only high index of suspicion with radiological support would be helpful in early diagnosis. Early cases may be benefited with progestin or Anti-aromatase therapy, most cases need surgery, either laparoscopically or laparotomy

Escitalopram reduces severity of depression and improves quality of life in patients with chronic obstructive pulmonary disease in an open label parallel group study

Background: Chronic obstructive pulmonary disease (COPD) is characterised by progressive and persistent airflow limitation with frequent exacerbations and hospitalizations contributing to overall morbidity and mortality. We evaluated the efficacy of antidepressant escitalopram therapy in depressed individuals suffering from chronic obstructive pulmonary disease.Methods: The sample comprised of sixty patients. Thirty patients received antidepressant escitalopram, while the remaining half served as controls. Hamilton depression rating and WHO–BREF questionnaire were the tools to assess severity of depression and quality of life. The severity of COPD was recorded using spirometry (FEV1%). Clinical assessments were at baseline and at week-2 and week-8 of follow up in both intervention and control groups.Results: It was found that both the groups were similar on the severity of the illness (COPD) at entry. FEV 1% of both the groups showed similar improvement after 8 weeks. Treatment with escitalopram showed a significant decrease in the severity of depression score and improvement on all the domains of quality of life when compared with the baseline. After the intervention, it was found that the HAM-D scores in the experimental group decreased from 24.44 to 17.50 while in the control group, it was from 20.11 to 19.67.  The magnitude of improvement was significantly higher with intervention compared to controls.Conclusions: Escitalopram reduces severity of depression and improves quality of life which was independent of improvement in FEV1. It could be asserted that this antidepressant improved the patient’s mood, fatigue and helplessness, which could have improved the quality of life of these patients

Region-based Convolutional Neural Network Driven Alzheimer’s Severity Prediction

It's important to note that Alzheimer's disease can also affect individuals over the age of 60, and in fact, the risk of developing Alzheimer's increases with age. Additionally, while deep learning approaches have shown promising results in detecting Alzheimer's disease, they are not the only techniques available for diagnosis and treatment. That being said, using Region-based Convolutional Neural Network (RCNN) for efficient feature extraction and classification can be a valuable tool in detecting Alzheimer's disease. This new approach to identifying Alzheimer's disease could lead to a more accurate and personalized diagnosis. It can also help in early treatment and intervention. However, it's still important to continue developing new methods and techniques for this disorder. Considering this our work proposes an innovative Region-based Convolutional Neural Network Driven Alzheimer’s Severity Prediction approach in this paper. The exhaustive experimental result carried out, which proves the efficacy of our Alzheimer prediction system

Cyclical hematuria-ureteral endometriosis: a case report

Little attention has been paid for the renal involvement in endometriosis, a rare and silent disorder which ultimately lead to renal failure. Involvement most commonly may be limited to single ureter (left one) and it is usually involvement extrinsically. Although cases have been reported in the literature, true incidence of ureteral involvement is still not known. The diagnosis is difficult as the disease has non-specific symptoms. Only high index of suspicion with radiological support would be helpful in early diagnosis. Early cases may be benefited with progestin or Anti-aromatase therapy, most cases need surgery, either laparoscopically or laparotomy

Escitalopram reduces severity of depression and improves quality of life in patients with chronic obstructive pulmonary disease in an open label parallel group study

Background: Chronic obstructive pulmonary disease (COPD) is characterised by progressive and persistent airflow limitation with frequent exacerbations and hospitalizations contributing to overall morbidity and mortality. We evaluated the efficacy of antidepressant escitalopram therapy in depressed individuals suffering from chronic obstructive pulmonary disease. Methods: The sample comprised of sixty patients. Thirty patients received antidepressant escitalopram, while the remaining half served as controls. Hamilton depression rating and WHO and ndash;BREF questionnaire were the tools to assess severity of depression and quality of life. The severity of COPD was recorded using spirometry (FEV1%). Clinical assessments were at baseline and at week-2 and week-8 of follow up in both intervention and control groups. Results: It was found that both the groups were similar on the severity of the illness (COPD) at entry. FEV 1% of both the groups showed similar improvement after 8 weeks. Treatment with escitalopram showed a significant decrease in the severity of depression score and improvement on all the domains of quality of life when compared with the baseline. After the intervention, it was found that the HAM-D scores in the experimental group decreased from 24.44 to 17.50 while in the control group, it was from 20.11 to 19.67. The magnitude of improvement was significantly higher with intervention compared to controls. Conclusions: Escitalopram reduces severity of depression and improves quality of life which was independent of improvement in FEV1. It could be asserted that this antidepressant improved the patient's mood, fatigue and helplessness, which could have improved the quality of life of these patients. [Int J Basic Clin Pharmacol 2016; 5(2.000): 281-284